Retinol binding protein-4 (RBP4) is a serum protein involved in the transport of vitamin A. It is known to be produced by the liver and white adipose tissue. RBP4 release by white fat has been proposed to induce insulin resistance. We analyzed the regulation and production of RBP4 in brown adipose tissue. RBP4 gene expression is induced in brown fat from mice exposed to cold or treated with peroxisome proliferator-activated receptor (PPAR) agonists. In brown adipocytes in culture, norepinephrine, cAMP, and activators of PPAR␥ and PPAR␣ induced RBP4 gene expression and RBP4 protein release. The induction of RBP4 gene expression by norepinephrine required intact PPAR-dependent pathways, as evidenced by impaired response of the RBP4 gene expression to norepinephrine in PPAR␣-null brown adipocytes or in the presence of inhibitors of PPAR␥ and PPAR␣. PPAR␥ and norepinephrine can also induce the RBP4 gene in white adipocytes, and overexpression of PPAR␣ confers regulation by this PPAR subtype to white adipocytes. The RBP4 gene promoter transcription is activated by cAMP, PPAR␣, and PPAR␥. This is mediated by a PPAR-responsive element capable of binding PPAR␣ and PPAR␥ and required also for activation by cAMP. The induction of the RBP4 gene expression by norepinephrine in brown adipocytes is protein synthesis dependent and requires PPAR␥-coactivator-1-␣, which acts as a norepinephine-induced coactivator of PPAR on the RBP4 gene. We conclude that PPAR␥-and PPAR␣-mediated signaling controls RBP4 gene expression and releases in brown adipose tissue, and thermogenic activation induces RBP4 gene expression in brown fat through mechanisms involving PPAR␥-coactivator-1-␣ coactivation of PPAR signaling. (Endocrinology 153: 1162-1173, 2012) 
as an adipokine, i.e. a protein released by adipose tissue with regulatory functions distinct from its role in vitamin A homeostasis (3) . A negative correlation between RBP4 levels (and, specifically, synthesis in WAT) and overall insulin sensitivity has been reported in several rodent models of obesity, and it has been proposed that RBP4 released by WAT acts on liver as a systemic signal promoting insulin resistance. In humans, obesity and the associated insulin resistance have been described as being associated with abnormally high RBP4 protein levels in serum, whereas insulin sensitization achieved via weight loss or exercise appears to reduce serum RBP4 levels (4). However, not all studies in humans have confirmed the relationship of obesity and insulin resistance with RBP4 levels (5) (6) (7) (8) (9) , and the role of RBP4 as a putative adipokine inducing insulin resistance remains controversial. Moreover, it has been recently reported that the RBP4-vitamin A complex inhibits cellular insulin responses through the interaction with the membrane protein stimulated by retinoic acid 6 present in the cell surface (10) .
The two main types of adipose tissue in mammals, WAT and brown adipose tissue (BAT) play opposing roles in energy balance. WAT is an energy-storing tissue, and BAT constitutes a site of energy expenditure due to its thermogenic capacity. Both types of adipose tissue are present in substantial amounts in adult rodents. In adult humans, WAT is predominant, but BAT has been recognized recently to have also a relevant presence (11, 12) . Both types of adipose tissue store vitamin A derivatives and have functions in metabolism of retinoids, including release of retinol (13) . All-trans retinoic acid acts usually as an antiadipogenic agent in brown and white adipocyte differentiation (14, 15) . However, retinoids participate in the differential development of both types of adipose tissues. Thus, all-trans retinoic acid, acting through retinoic acid receptors (RAR), is a powerful inducer uncoupling protein-1 (UCP1) expression, the specific marker of brown-vs.-white fat and responsible for thermogenic function (16) . On the other hand, activation of the retinoid X receptor (RXR) by 9-cis retinoic acid favors brown and white adipogenesis through activation of the RXR moiety of the adipogenic peroxisome proliferator-activated receptor (PPAR)␥/RXR heterodimers (17) . PPAR␣ is highly expressed in BAT, whereas expression in WAT is very low (18) . PPAR␣ controls the transcription of genes for lipid catabolism in brown fat as well as UCP1 gene transcription, and it has been proposed that it establishes a link between lipid oxidation and thermogenesis in BAT (19) .
The major pathway of control of brown fat-specific thermogenic activity involves the action of norepinephrine, released by the sympathetic nervous system (20) . The activation of ␤-adrenergic receptors leads to a rise in intracellular cAMP, which mediates most of the thermogenic responses of the brown adipocyte, i.e. enhanced lipolysis and induction of UCP1 gene expression.
The molecular signals controlling RBP4 gene expression and synthesis in adipose tissues are poorly understood. Treatment of rodents with rosiglitazone, an activator of PPAR␥, has been reported to reduce RBP4 gene expression in WAT, an effect contributing to the insulin sensitizing effects of this drug (3) . However, other reports in humans do not support such an effect, and treatment of human patients with the thiazolidinedione (TZD) pioglitazone, another activator of PPAR␥, has been reported to increase RBP4 gene expression in WAT (8, 21) .
In the present study, we show that RBP4 gene expression is under the control of PPAR␣ and PPAR␥-mediated regulation as well as by noradrenergic, cAMP-mediated, stimulus involving PPAR␥-coactivator-1-␣ (PGC-1␣) in brown adipocytes These pathways of control may contribute to the differential regulation of RBP4 gene expression and protein release by BAT and WAT.
Materials and Methods
Wy14,643, bezafibrate, GW7647, GW501516, GW6471, GW9662, all-trans and 9-cis retinoic acid, norepinephrine, dibutyryl-cAMP, and cycloheximide were from Sigma (St. Louis, MO). Rosiglitazone was from Cayman (Ann Arbor, MI). The care and use of mice were in accordance with the European Community Council Directive 86/609/EEC. For studies in lactating dams, Swiss mice 15 d after parturition were injected with a single dose of Wy14,643 [50 g/g body weight (bw)] or bezafibrate (100 g/g bw) in 20% dimethylsulfoxide/saline, or equivalent volumes of vehicle solution, and killed 6 h later. To determine the effects of cold exposure, two-month-old PPAR␣-null mice and strain-matched wild-type mice were acclimated to a thermoneutral temperature (28 C) for 1 wk and then exposed to 4 C for 24 h. Interscapular BAT, periovarian WAT, and liver were dissected for further analysis.
RNA was extracted from BAT, WAT, liver, and cultured cells (RNAeasy kit; QIAGEN, Valencia, CA). RT was performed in 20 l, using random hexamer primers (Applied Biosystems, Foster City, CA) and 0.5 g of RNA. PCR were conducted in the ABI/Prism-7700 Sequence-Detector System using 25 l of reaction mixture containing 1 l of cDNA, 12.5 l of TaqMan Universal PCR Master Mix, 250 nM probes, and 900 nM primers from the following Assays-on-Demand (Applied Biosystems) kits: Mm00803266, mouse RBP4; Hs00198830, human RBP4; Mm00447183, PGC-1␣; and Hs99999901, 18S rRNA. Each sample was run in duplicate, and the mean value of the duplicate was normalized to that of the 18S rRNA gene using the comparative (2 Ϫ⌬CT ) method following the manufacturer's instructions. Primary brown adipocytes were differentiated in culture as described previously (16) . Brown adipocytes were exposed to treatments, and cells and medium were harvested 24 h later, unless otherwise indicated. The HIB-1B brown adipocyte cell line was cultured as reported elsewhere (22) . Primary cultures of mouse white adipocytes were performed using preadipocytes isolated from mouse sc WAT, as described (23) . Experiments were performed on d 12 of differentiation, and cells and medium were harvested 24 h after treatment. SGBS human adipocyte cells were cultured and differentiated as already reported (24) , and experiments were performed on d 12 after induction of differentiation, when more than 70% cells were differentiated.
Mouse embryonic fibroblasts (MEF) were isolated from 13-d-old (embryonic age) wild-type and PGC-1␣-null mice (kindly provided by B. Spiegelman) according to standard procedures, and adipogenic differentiation of MEF was achieved as already described, with slight modifications (25, 26) . Experiments were performed when 80 -90% of the cells were differentiated, on the basis of acquisition of adipocyte morphology.
The plasmids Ϫ1192-RBP4-Luc, Ϫ535-RBP4-Luc, and Ϫ285-RBP4-Luc, in which the corresponding human RBP4 promoter fragments drive Firefly luciferase, have been described previously (27) . The plasmid Ϫ1192-Mut-RBP4-Luc is a version of Ϫ1192-RBP4-Luc, in which point mutations to disrupt the putative PPAR-responsive element at position Ϫ765/Ϫ745 had been included. The point mutant construct was generated using a QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA), the forward primer 5Ј-GAA ACT AAA GAA CAA ATA TTG Aagc GAG GGa cCC ACA ACG CTC CTG AAA GAG AG-3Ј, and 5Ј-CTC TCT TTC AGG AGC GTT GTG GGT CCC TCG CTT CAA TAT TTGTTCTTTAGTTTC-3Ј (lower case indicates the mutated base pairs), the complementary reverse primer. The plasmids were transfected into HIB-1B cells using FuGENE 6 (Roche, Indianapolis, IN). Each point was assayed in triplicate and contained 0.3 g of RBP4-Luc reporter plasmid, 0.5 ng of the expression vector pRL-CMV (Promega, Madison, WI), and, when indicated, 0.06 g of pSG5-PPAR␣, pSG5-PPAR␥, or pSV-PGC-1␣. Cells were incubated for 48 h after transfection and, when indicated, treated for 24 h with 1 M GW7647, 10 M rosiglitazone, or 1 mM dibutyryl-cAMP. Luciferase activities were measured using the Dual-Luciferase-Reporter assay (Promega). Firefly luciferase activity was normalized for transfection efficiency using Renilla luciferase as an internal control.
Differentiated primary brown adipocytes were transduced with an adenoviral vector expressing RNA interference against PGC-1␣ (28) or a scrambled RNA sequence as a control. Multiplicity of infection was 200, and cells were exposed 24 h after transduction to 0.5 M norepinephrine for 6 h. Differentiated SGBS adipocytes were transduced with adenoviral vectors driving human PPAR␣ (AdCMV-hPPAR␣) (29) , murine PGC-1␣ (AdCMV-PGC-1␣, provided by B. Spiegelman), or green fluorescent protein (GFP) (AdCMV-GFP, control) at a multiplicity of infection of 400, for 4 h. Experiments were performed after further incubation in differentiation medium for 48 h. Efficiency of transduction was approximately 80%, on the basis of GFP fluorescence. Cells were treated for 24 h with 1 M GW7647, 10 M rosiglitazone, or vehicle (dimethylsulfoxide).
Immunoblot analysis of RBP4 protein in cell culture medium (35 l) was performed using 13% SDS-PAGE, RBP4 antiserum reacting against human or mouse RBP4 (1:2000; Alexis, San Diego, CA), and the enhanced chemiluminescence detection kit (Amersham, Piscataway, NJ). Quantitative analysis was performed by densitometry (Phoretics ID Software, Newcastle, UK). Quantification of mouse RBP4 plasma levels was performed using a specific ELISA kit (AdipoGen, Incheon, Korea).
Chromatin immunoprecipitation (ChIP) experiments were performed as described elsewhere (30) . HIB-1B cells were transfected with the RBP4 promoter constructs, pSG5-PPAR␣ or pSG5-PPAR␥, and exposed to 1 M GW7647 or 10 M rosiglitazone, respectively, as described above. Immunoprecipitation was carried out using anti-PPAR␣ (sc-9000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) or anti-PPAR␥ (sc-7196; Santa Cruz Biotechnology, Inc.) antibodies or an equal amount of an unrelated immunoglobulin (Sigma). Input DNA and immunoprecipitated DNA were analyzed by quantitative PCR using SYBR green fluorescent dye and the following primers encompassing the putative PPAR-responsive region in the RBP4 gene: forward, 5Ј-ACC AGG GTT GCG TTT CTG GAG AAT-3Ј; reverse, 5Ј-TCT GAG GTC CAC TTG TGC AGG AAT-3Ј. Primers amplifying a 237-bp fragment of the cyclophilin-A gene, used as control, were: forward, 5Ј-CCA TCC AGC CAT TCA GTC TT-3Ј and reverse, 5Ј-TTA CAG GAC ATT GCG AGC AG-3Ј. The protein-bound DNA was calculated as a ratio to input DNA. The specificity of amplification using the primers above was assessed by PCR amplification (30 cycles of 30 sec at 95 C, 30 sec at 60 C, and 30 sec at 72 C), electrophoreses on 1.5% agarose gel, and staining with ethidium bromide and visualization of the expected bands. For ChIP analysis of the endogenous RBP4 gene promoter, we followed essentially the same procedures, but HIB-1 cells were not transfected with the RBP4 promoter plasmids, and a DNA fragment, encompassing the corresponding PPAR-responsive region in the mouse RBP4 gene promoter, was amplified using the specific primers: forward, 5Ј-GCT TCT ACT GAG GAG CTG TTG TG-3Ј; and reverse, 5Ј-GGA CGA TCA ACC ACT CGG CCA TTG-3Ј.
Where appropriate, statistical analysis was performed using the Student's t test; significance is indicated in the text.
Results

RBP4 gene expression and induction by thermogenic activation in mouse BAT
Basal expression of RBP4 mRNA was not significantly different between BAT and WAT in mice reared at thermoneutral temperature. Exposure of mice to cold (4 C) caused a significant increase in RBP4 mRNA levels in BAT, whereas no effects were observed in WAT (Fig. 1A) . In fact, mice placed at the usual room temperature (21 C), in which a mild thermogenic stimulus occurs, showed significantly higher levels of RBP4 mRNA in BAT than in WAT (3 Ϯ 0.25-fold, P Ͻ 0.05), thus confirming the sensitivity of the RBP4 gene to the thermogenic stimulus in BAT. However, exposure of mice to a 4 C environment caused a significant reduction in RBP4 gene expression in the liver from cold-exposed mice (65 Ϯ 13% RBP4 mRNA levels respect to thermoneutral liver, P Ͻ 0.05). Plasma levels of RBP4 were lowered in cold-exposed mice (54.5 Ϯ 4.6 g/ml) respect to thermoneutral controls (78.1 Ϯ 2.4 g/ml, P Ͻ 0.05).
The effects of acute treatment of mice with drugs distinct from a noradrenergic stimulus but known to influence brown fat activity, i.e. PPAR activators, were studied. Previous studies have indicated that the action on BAT of acute treatment of mice with PPAR activators was optimally visualized when controls were mice in a physiological state involving low levels of circulating free fatty acids, i.e. lactating dams (19) . Thus, when lactating mice were treated with a single dose of bezafibrate, a PPAR activator with poor selectivity for PPAR subtypes, a significant rise in RBP4 mRNA was observed (Fig. 1B) . The PPAR␣-specific activator Wy14,643 also significantly induced RBP4 mRNA levels. To further establish the role of PPAR␣ in the control of RBP4 gene expression in BAT, PPAR␣-null mice were studied. No differences in RBP4 mRNA levels were observed in BAT from mice in basal, thermoneutral conditions (Fig. 1C) . However, cold exposure caused a minor induction of RBP4 mRNA levels in PPAR␣-null mice relative to controls (Fig. 1C) , thus suggesting an interaction between noradrenergic and PPAR-dependent pathways of control of the RBP4 gene in BAT. In liver, levels of RBP4 mRNA expression were lower in PPAR␣-null respect to wild-type mice in thermoneutral conditions and were similarly lowered by cold exposure (Table 1) . Plasma levels of RBP4 in PPAR␣-null mice were reduced respect to wild-type mice in thermoneutral conditions and after cold exposure ( Table 1) .
Effects of noradrenergic activation, PPAR agonists, and retinoids on RBP4 gene expression in brown adipocytes
Norepinephrine as well as cAMP caused a dramatic induction of RBP4 mRNA levels in brown adipocytes in primary culture. Bezafibrate, PPAR␣ (GW7647), and PPAR␥ (rosiglitazone)-specific activators also significantly induced RBP4 mRNA levels, whereas a PPAR␤/␦ activator (GW501516) did not ( Fig. 2A) . Both 9-cis retinoic acid and a synthetic activator of RXR, AGN194204 (a gift from R. Chandraratna), also increased RBP4 mRNA abundance. In contrast neither all-trans retinoic acid nor TTNPB, a specific activator of RAR, induced RBP4 mRNA expression. To establish the consequences of the increase in RBP4 mRNA levels, RBP4 protein levels FIG. 1. RBP4 mRNA levels in brown and WAT. Effects of thermogenic stimulus and PPAR␣-dependent stimulation. A, RBP4 mRNA levels in BAT and WAT from Swiss mice maintained at thermoneutral temperature (28 C) (TN) or exposed to 4 C ambient temperature during 24 h. B, RBP4 mRNA levels in BAT from lactating mice 6 h after treatment with a single injection of Wy14,643 (50 g/g bw) or bezafibrate (100 g/g bw) (BZ). C, RBP4 mRNA levels in BAT from PPAR␣-null and wild-type mice exposed to 4 C ambient temperature over 24 h. Bars indicate the mean Ϯ SEM of six to seven mice from at least three different litters. Data are shown as fold-induction relative to control values for each panel. Significant differences between controls and cold exposed (A and C) or with respect to drug-injected mice (B) are shown by *, P Ͻ 0.05; and the comparison between wild-type and PPAR␣-null mice by #, P Ͻ 0.05. DMSO, Dimethylsulfoxide. were determined in brown adipocyte culture medium. Results indicated that norepinephrine, cAMP, bezafibrate, and the PPAR␥-specific (rosiglitazone) and PPAR␣-specific (GW7647) activators caused a significant rise in the abundance of RBP4 protein in the medium (Fig. 2B) .
To further analyze the role of PPAR␣ in the control of the RBP4 gene and its interaction with the cAMP-dependent, noradrenergic pathway of regulation, primary cultures of brown adipocytes were established from PPAR␣-null mice (Fig. 3) . Morphological differentiation of adipocytes from PPAR␣-null mice was unaltered respect to cultures from wild-type mice, as described elsewhere (31) . Basal levels of RBP4 mRNA expression were also unaltered in PPAR␣-null brown adipocytes, whereas the increase in RBP4 mRNA levels due to the PPAR␣ agonist GW7647 was completely suppressed (Fig. 3) . The effects of the RXR activator AGN194204 were essentially unchanged, and the action of 9-cis retinoic acid and of rosiglitazone was slightly reduced. The effects of norepinephrine, although not completely impaired, were significantly reduced in adipocytes lacking PPAR␣, thus further indicating a cross talk between PPAR␣-dependent and noradrenergic pathways of regulation of RBP4 gene expression (Fig. 3) .
In a second approach, the PPAR␣ antagonist GW6471 was used. This drug not only suppressed the action of the PPAR␣ activator GW7647, but it also significantly reduced the action of norepinephrine (Fig. 4) . The PPAR␥ antagonist GW9662 also significantly decreased the effects of norepinephrine on RBP4 mRNA expression, whereas treatment with both PPAR subtype-specific drugs completely suppressed noradrenergic induction. This indicated that an active PPAR-dependent pathway of regulation, either through PPAR␣ or PPAR␥, is required for effective noradrenergic induction of the RBP4 gene in brown adipocytes.
Transcriptional control of the RBP4 gene by PPAR and cAMP in brown adipocytes
To determine the action of cAMP and PPAR␣-dependent pathways in transcriptional control of the RBP4 gene in brown adipocytes, transfection assays on HIB-1B 
FIG. 3.
Responsiveness of RBP4 gene expression to hormonal agents in brown adipocytes lacking PPAR␣. RBP4 mRNA levels in mouse brown adipocytes obtained from wild-type and PPAR␣-null mice and exposed to the indicated agents (see Fig. 2A) . Bars indicate the mean Ϯ SEM of four to six independent cell cultures for each condition. Data are shown as fold-induction relative to values in nontreated cells from wild-type mice. Significant differences between each treatment condition and nontreated cells (C) for each genetic background are indicated by *, P Ͻ 0.05, and those between wild-type and PPAR␣-null cells for each treatment condition by #, P Ͻ 0.05. NE, Norepinephrine; RA, retinoic acid; Rosi, rosiglitazone.
brown fat-derived cells were performed using a luciferase construct driven by the 1192-bp promoter region of the human RBP4 gene. Exposure of the transfected construct to PPAR activators indicated significant induction by PPAR␥ activation (rosiglitazone), a weaker but significant induction by PPAR␣ activation (GW7647), and a significant induction due to cAMP (Fig. 5A) . Cotransfection with PPAR␣, and particularly further addition of GW7647, caused a dramatic induction of the RBP4 promoter activity. Similar observations were obtained when PPAR␥ was cotransfected and cells were exposed to rosiglitazone. No effects were observed with PPAR␤/␦ cotransfection, further indicating the lack of sensitivity of the RBP4 gene to this PPAR subtype (data not shown).
Through a deletion mutant analysis, it was determined that the RBP4 promoter construct lacking the fragment from Ϫ1192 to Ϫ535 retained most of the basal activity but became completely nonsensitive to PPAR-dependent regulation (Fig. 5A) . Most of cAMP-mediated responsiveness was lost in this short Ϫ535-RBP4-Luc construct. Further deletion of the reporter construct between Ϫ535 and Ϫ285 dramatically reduced basal promoter activity (11% of the full-length construct levels), and Ϫ285-RBP4-Luc was completely insensitive to PPAR-or cAMP-dependent regulation (data not shown). The Ϫ1192 to Ϫ535 region of the RBP4 gene was previously reported to contain a putative PPAR-responsive sequence at Ϫ765 to Ϫ745 (27) . When we analyzed a construct of the RBP4 promoter in which point mutations had been introduced to disrupt PPAR binding at this site (Ϫ1192-Mut-RBP4-Luc) (Fig.  5C) , the responsiveness to PPAR and to cAMP was essentially lost (Fig. 5A) . ChIP in conditions of PPAR-dependent induction of the RBP4 promoter in HIB-1B cells using antibodies against PPAR␣ and PPAR␥ indicated a specific enrichment in the PCR amplification of both the endogenous and the transfected RBP4 promoter region (Fig. 5B) . When Ϫ1192-Mut-RBP4-Luc mutated version of the RBP4 promoter construct was analyzed in comparison with the wild-type promoter construct, a significant impairment in the enrichment of amplified DNA after ChIP using PPAR␣ and PPAR␥ antibodies was observed (Fig.  5D) . Collectively, this data indicate that PPAR␣ and PPAR␥ regulate the RBP4 gene promoter mainly through the Ϫ765 to Ϫ745 region of the RBP4 gene.
Regulation of RBP4 gene expression in white adipocytes
We determined whether the observed effects were specific to brown adipocytes or were shared by white adipose cells. Differentiated 3T3-L1 and 3T3-F442A adipocytes express extremely low levels of RBP4 mRNA, hardly detectable even using highly sensitive quantitative real-time PCR. In contrast, mouse white adipocytes differentiated in primary culture expressed substantial levels of RBP4 mRNA. Norepinephrine and the PPAR␥ agonist rosiglitazone significantly induced RBP4 mRNA levels in white adipocytes, whereas the PPAR␣ activator GW7647 had no effect (Fig. 6A ). Parallel observations were made for RBP4 protein levels in the adipocyte culture medium in response to these agents (Fig. 6B) . The study of SGBS human white adipocytes led essentially to similar results (Fig.  6C ). This indicated that the main features of regulation of RBP4 gene expression in white adipocytes were shared by human and murine cells.
The lack of effect observed for the PPAR␣ agonist on RBP4 gene expression in white adipocytes was likely to be due to the much lower expression of PPAR␣ in white, in comparison with brown, adipocytes (18) . We therefore investigated whether increasing PPAR␣ expression in white adipocytes could confer to these cells sensitivity to activation of RBP4 gene expression. Adenoviral transduction of human SGBS white adipocytes led to highly PPAR␣ expression, with levels around 30-fold those in basal conditions. PPAR␣ expression led to a significant induction of RBP4 mRNA levels in SGBS white adipocytes after exposure to GW7647 (Fig. 6D) . This confirmed the positive action of PPAR␣ on the RBP4 gene in the context of adipose cells, either brown or white.
Effects of PGC-1␣ on RBP4 gene regulation
The requirement of intact PPAR signaling pathway for cAMP responsiveness of RBP4 gene expression led us to study whether the effects of noradrenergic, cAMP-depen- dent, stimulus of the RBP4 gene in brown adipocytes could occur through indirect processes. Treatment of brown adipocytes with cycloheximide, a suppressor of protein synthesis, blunted RBP4 mRNA induction in response to norepinephrine (Fig. 7A) , indicating that, effectively, RBP4 mRNA induction was protein-synthesis dependent. We examined the role of PGC-1␣ in RBP4 gene regulation in brown adipocytes, considering that PGC-1␣ expression is induced by norepinephrine in brown adipocytes via cAMP-dependent signaling and it is a powerful coactivator of PPAR␣ and PPAR␥ (32) . The time course of norepinephrine effects on gene expression in brown adi-
FIG. 5.
Effects of PPAR␣ and PPAR␥ activation and of cAMP on RBP4 promoter. A, HIB-1B cells were transfected with the Ϫ1192-RBP4-Luc plasmid, the deleted plasmid construct Ϫ535-RBP4-Luc, or the Ϫ1192 hRBP4-Mut-Luc mutated version (see C) and, when indicated, were cotransfected with the plasmid expression vectors for PPAR␣ or PPAR␥ and exposed to the PPAR␣ activator GW7647, the PPAR␥ activator rosiglitazone, and 1 mM dibutyryl-cAMP (cAMP). Bars indicate the mean Ϯ SEM of normalized luciferase activity (see Materials and Methods). Significant differences (P Ͻ 0.05) due to PPAR agonists or cAMP relative to controls for each construct and cotransfection setting are shown by *, those due to PPAR␣ or PPAR␥ for each condition are shown by #, and those between wild-type and mutated forms of the promoter constructs at the same condition are shown by ⌬. B, ChIP of PPAR␣ and PPAR␥ binding to RBP4 gene promoter. HIB-1B cells were analyzed without transfection of promoter constructs (analysis of the endogenous murine RBP4 gene promoter) or after transfection with the Ϫ1192-RBP4-Luc. PPAR␣ and PPAR␥ expression vectors were cotransfected, and cells were treated with 1 M GW7647 and 10 M rosiglitazone (Rosi), respectively. PPAR␣ or PPAR␥ antibodies (Ab) or an unrelated IgG were used to immunoprecipitate the protein-DNA complexes. Bars are mean Ϯ SEM of relative enrichment of the PCR amplification signals due the PPAR antibodies respect to IgG (top). Significant differences respect to IgG are shown by *, P Ͻ 0.05. An example of PCR amplification in the ChIP assay is shown (bottom). RBP4 indicates the amplified DNA corresponding to the RBP4 promoter region, and Cyp, that corresponding to the cyclophilin-A gene used as control (see Materials and Methods). C, Sequence of the PPAR responsive element in the RBP4 promoter; site-directed mutations to generate 1192-RBP4-Mut-Luc are shown in lower case. D, ChIP of PPAR␣ and PPAR␥ binding to the wild-type and mutant forms of the RBP4 gene promoter. HIB-1B cells were transfected and treated as in B but including either the Ϫ1192-RBP4-Luc or Ϫ1192-RBP4-Mut-Luc plasmids. Bars are mean Ϯ SEM of relative enrichment of the PCR amplification signal respect to input. Significant differences between the wild-type (wt) and the mutated (mut) promoter constructs are shown by *, P Ͻ 0.05. pocytes showed a much earlier peak of induction of PGC-1␣ mRNA than RBP4 mRNA (Fig. 7B) . Cycloheximide did not suppress PGC-1␣ mRNA induction (17-fold induction of PGC-1␣ mRNA in the presence of cycloheximide vs. 15-fold induction in the absence, 2-h exposure to norepinephrine). These results were compatible with the hypothesis that PGC-1␣ may play a role in stimulus of the RBP4 gene in response to noradrenergic cAMP-mediated signaling, via coactivation of PPAR. This possibility was assessed by determining the effects of impairing PGC-1␣ expression in the responsiveness of the RBP4 gene to norepinephrine. Adenoviral-mediated expression of PGC-1␣ small interfering RNA (siRNA) reduced PGC-1␣ mRNA levels to 31 Ϯ 5% respect to those in controls transduced with scrambled siRNA. Under these conditions, the capacity of norepinephrine to induce RBP4 mRNA expression was significantly impaired (Fig. 7C) . The role of PGC-1␣ in mediating RBP4 gene expression was explored further by studying the effects of cAMP on adipocytes derived from MEF obtained from wild-type and PGC-1␣-null mice. Adipocytes from wild-type MEF exhibit an intermediate brown-to-white adipocyte phenotype, including the expression of substantial levels of PGC-1␣ (see Refs. 26, 33 and present results). After adipogenic differentiation, MEF from wild-type and from PGC-1␣-null mice acquired adipose morphology and expressed marker genes of adipogenesis, such as ap2 mRNA or PPAR␥ (data not shown) similarly, as expected from a previous report using RNA interference-mediated PGC-1␣ invalidation systems (34) . Basal expression of RBP4 mRNA was slightly impaired in PGC-1␣-null adipocytes (71 Ϯ 28% respect to wild-type adipocytes). Adipocytes derived from PGC-1␣-null embryos showed a significant impairment in cAMP-mediated induction of RBP4 mRNA expression (Fig. 7D) , thus indicating that PGC-1␣ is required for cAMP-mediated regulation of the RBP4 gene. A further analysis using transfection of HIB-1B cells was undertaken. PGC-1␣ cotransfection induced RBP4 gene promoter activity as well as enhanced the activation elicited by rosiglitazone and PPAR␥ cotransfection (Fig. 7E) . Similar results were observed for PPAR␣ and GW7647 effects (data not shown). The effects of PGC-1␣ cotransfection were lost for the Ϫ1192 hRBP4-Mut-Luc construct, in which the PPAR responsive region is mutated. Finally, the   FIG. 6 . Effects of hormonal agents on RBP4 mRNA and protein levels in murine white adipocytes differentiated in primary culture and in differentiated human SGBS white adipocytes. A, RBP4 mRNA levels in mouse white adipocytes differentiated in primary culture and exposed to the indicated agents (see Materials and Methods). B, RBP4 protein in culture medium from white adipocytes differentiated in culture. C, RBP4 mRNA levels in human SGBS white adipocytes differentiated in culture and exposed to the indicated agents and concentrations (see legend to effects of PGC-1␣ on RBP4 gene expression were analyzed in SGBS white adipocytes, which lack a substantial expression of PGC-1␣ in contrast with brown adipocytes but express PPAR␥. Adenoviral-mediated overexpression of PGC-1␣ was enough to cause a significant induction of RBP4 mRNA expression (Fig. 7F) .
Discussion
The present study demonstrates that RBP4 gene expression is tightly regulated in BAT by cAMP-mediated pathways, PPAR␥ and PPAR␣. Moreover, the present findings supports the notion that, in contrast to other adipokines that are preferentially released by white (rather than brown) adipocytes, substantial RBP4 expression and release occurs in BAT, specially after thermogenic activation.
The cAMP-dependent regulation observed in brown adipocytes may be related to the induction of RBP4 gene expression by the thermogenic stimulus in BAT. A likely scenario after thermogenic stimulus would be that enhanced lipolysis results in increased hydrolysis of retinylesters inside the fat depots of BAT, with the subsequent release of retinol and the potential need for coordinate synthesis of the RBP4 protein to bind it. The capacity of BAT to become an enhanced source of retinol and/or RBP4 protein in response to thermogenic stress has not been analyzed to date, but it might be expected to occur on the basis of the present findings. However, the physiological significance of RBP4 expression and release by BAT under conditions of enhanced thermogenic activity is unclear at present. We observed that serum RBP4 levels were reduced in mice exposed to cold, in association with reduced RBP4 gene expression in liver. In general, changes in serum . Data are expressed as fold-induction relative to 0 h. A and B, Points are means from two to three independent experiments with triplicate plates, in which the variation within the experimental groups was less than 15%. C, Brown adipocytes were transduced with an adenoviral vector driving PGC-1␣ siRNA or an adenoviral vector driving scrambled siRNA (control siRNA) and exposed or not to 0.5 M norepinephrine (NE) for 6 h. Bars are mean Ϯ SEM of relative RBP4 mRNA levels in four independent assays. Statistical differences due to NE in each condition are shown as *, P Ͻ 0.05 and those due to PGC-1␣ siRNA as #, P Ͻ 0.05. D, Adipocytes derived from MEF from PGC-1␣-null and wild-type littermates were exposed to 1 mM dibutyryl-cAMP for 3, 6, and 24 h, and induction of RBP4 mRNA expression was expressed as mean Ϯ SEM. Statistical differences between PGC-1␣-null and wild-type adipocytes are shown as *, P Ͻ 0.05. E, HIB-1B cells were transfected with the Ϫ1192-RBP4-Luc or Ϫ1192-RBP4-MutLuc plasmids and, when indicated, cotransfected with the plasmid expression vectors for PPAR␥ or PGC-1␣ and exposed to the PPAR␥ activator rosiglitazone (Rosi). Bars indicate the mean Ϯ SEM of normalized luciferase activity. Significant differences (P Ͻ 0.05) in comparison with controls are shown by *, those due to both PPAR␥ and PGC-1␣ are shown by #, and those between wild-type and mutated form of the promoter at the same condition are sown by ⌬. F, RBP4 mRNA levels in SGBS human white adipocytes differentiated in culture transduced with adenoviral vectors driving PGC-1␣, or GFP as a control. Bars indicate the mean Ϯ SEM of RBP4 mRNA levels for four to five independent cell cultures for each condition. Data are expressed as fold-induction relative to nontreated, nonadenoviral-transduced cells (C).
RBP4 levels paralleled changes in liver RBP4 expression in our study, thus supporting a main role of liver RBP4 expression in determining circulating RBP4 levels. It is likely that lowered hepatic expression compensate for enhanced RBP4 production by BAT in conditions of thermogenic stress resulting ultimately in lower systemic levels. The possibility that increased production of RBP4 by BAT causes mainly local, autocrine/paracrine effects should deserve further research. In WAT, adrenergic induction of RBP4 gene expression and release might have a distinct physiological significance, because lipolysis in white fat is enhanced in response to starvation, a state of increased RBP4 levels in serum and reduced insulin action.
Our present findings indicate that PPAR␥ activation induces RBP4 expression by acting directly on the RBP4 gene promoter. This is in agreement with reports on the action of the PPAR␥-activating drugs pioglitazone and troglitazone in human adipocytes in culture (8, 21) . However, the effects of treatment with TZD on patient RBP4 levels are controversial, given currently conflicting data on the role of RBP4 in obesity and development of insulin resistance and type II diabetes (for a review of the current state of the controversies, see 35) . Lowered serum RBP4 levels have been reported after treatment of diabetic (36, 37) and HIV-1-infected (38) patients with pioglitazone or rosiglitazone. However, other studies did not record a significant reduction after pioglitazone treatment (39, 40) . In mice, chronic treatment with rosiglitazone lowers RBP4 serum levels but only in insulin-resistant mice (3). In patients, a single recent report showed increased RBP4 levels in WAT from pioglitazone-treated patients (8) . The apparently contradictory observations of a positive impact of TZD on RBP4 gene expression in adipose tissues shown here, and the lowered RBP4 circulating levels in several reports of TZD-treated patients, may be due to the complex turnover processes determining RBP4 levels in serum, for which release from adipose tissues is just one more component. Indirect effects of TZD on nonadipose sites of RBP4 release, or on degradation and renal clearance of RBP4, cannot be excluded and warrant further research. In any case, a direct antidiabetic action of TZD via reduction of RBP4 release by adipose cells is unlikely in light of the present findings.
The present results identify a novel pathway of regulation of RBP4 gene expression by the recognition of PPAR␣, and the corresponding activating drugs, as a powerful activators of RBP4 gene expression and release by brown adipocytes, the type of adipose cell with preferential expression of PPAR␣. The fact that the RBP4 gene is part of the cluster of PPAR␣-regulated genes, usually encoding lipid catabolism proteins, may be related to the aforementioned need for dealing with the free retinol appearing in BAT as a consequence of a high lipolysis during thermogenic activation. On the other hand, the identification of the RBP4 gene as a target of PPAR␣ in brown adipocytes should lead to exploration of whether this pathway is also active in liver, a main site of PPAR␣ and RBP4 gene expression, and a major target of fibrates, PPAR␣-activating drugs of current use in some dyslipidemias. Our present data indicating lowered expression of RBP4 mRNA in liver from PPAR␣-null mice is consistent with this possibility. In a recent study, chronic treatment of obese mice with the PPAR␣ agonist fenofibrate was reported to cause a reduction of RBP4 mRNA expression in WAT (41) , although it is unclear whether this was a direct or indirect effect as a consequence of long-term treatment "in vivo." In that report, the action of fenofibrate causing a slight decline in RBP4 mRNA expression in 3T3-L1 adipocytes should be considered to the light of the present findings and other previous reports (42) indicating an extremely low basal expression of RBP4, close to detection limits, in 3T3-L1 adipocytes.
A close interplay between the cAMP and PPAR-dependent pathways of regulation of the RBP4 gene in BAT is shown in the present study, and most of the cAMP action on RBP4 gene transcription requires intact PPAR-dependent pathways. A role for PPAR␣ in mediating noradrenergic, cAMP-dependent, regulation of gene transcription in BAT has been proposed (43, 44) , and it was attributed to the action of cAMP in promoting lipolysis and the intracellular generation of free fatty acid derivatives, natural activators of PPAR. However, modulation of PPAR␣ activity via protein kinase A-dependent phosphorylation cannot be excluded (45) . Nonetheless, our present data strongly support that it is PGC-1␣ induction by cAMP and the corresponding action of PGC-1␣ in coactivating PPAR␣ and/or PPAR␥ what determines most of the cAMP-dependent RBP4 gene regulation.
In summary, we report that PPAR␥ and PPAR␣, as well as cAMP, control RBP4 gene expression in brown adipocytes. Induction of PGC-1␣ expression by cAMP and subsequent coactivation of PPAR play a pivotal role in mediating cAMP effects. Drugs activating PPAR␥, such as TZD, promote RBP4 gene up-regulation in adipocytes. Fibrates, which act on PPAR␣, also control RBP4 gene expression in brown adipocytes. Taking into account the recent recognition of active BAT in adult humans (12) , further research will be required to establish the role of the induction of RBP4 gene expression and RBP4 protein release by BAT in the context of the overall systemic responsiveness to these drugs when used in the treatment of insulin resistance and dyslipidemias.
